Mirtazapine is the Safer Choice for Sleep in Patients with QT Prolongation
For a patient with prolonged QTc, mirtazapine is the preferred medication for insomnia over trazodone, as trazodone carries significantly higher cardiac risk with documented QT prolongation at therapeutic doses and established arrhythmogenic potential. 1
Key Cardiac Safety Differences
Trazodone's Cardiac Risks
Trazodone is explicitly contraindicated in patients with known QT prolongation according to FDA labeling, which states it "should be avoided in patients with a history of cardiac arrhythmias" and "in patients with known QT prolongation." 1
Trazodone prolongs the QT/QTc interval and has documented cases of torsades de pointes at doses as low as 100 mg or less. 1
Preclinical studies demonstrate trazodone inhibits hERG channel current with an IC50 of 0.69 μM at clinically relevant concentrations, directly prolonging the QT interval through this mechanism. 2
In toxicology surveillance, trazodone was statistically associated with QTc >500 ms in overdose situations. 3
Mirtazapine's Cardiac Profile
Mirtazapine demonstrates minimal QT effects at therapeutic doses. The FDA label notes that at 75 mg (1.67 times the maximum recommended dose), mirtazapine "does not prolong the QTc interval to a clinically meaningful extent." 4
A concentration-QTc study showed QTc prolongation of only 2.39 ms at 45 mg and 4.00 ms at 75 mg—levels "not at a level generally considered to be clinically meaningful." 5
Retrospective analysis of 61 medically hospitalized patients showed an average QTc change of only -0.31 ms with mirtazapine, with no adverse cardiac outcomes. 6
While the FDA label includes a warning about QTc prolongation, it specifically notes this occurs primarily "in association with overdose or in patients with other risk factors for QT prolongation." 4
Clinical Management Algorithm
Step 1: Baseline Assessment
- Measure baseline QTc before initiating either medication 7
- Optimize electrolytes (potassium, magnesium) to prevent additive QT risk 7
- Review all concomitant medications for QT-prolonging drugs 7
Step 2: Medication Selection
- Choose mirtazapine starting at 7.5-15 mg at bedtime for patients with baseline QTc prolongation 4
- Avoid trazodone entirely in this population given FDA contraindication 1
Step 3: Monitoring
- Repeat ECG during dose titration if using mirtazapine 7
- Discontinue if QTc reaches >500 ms or increases by >60 ms from baseline 7
- Avoid combining with other QTc-prolonging medications whenever possible 7
Important Caveats
Neither Drug is Recommended for Chronic Insomnia
The American Academy of Sleep Medicine guideline explicitly states trazodone is "not recommended for treating either sleep onset or sleep maintenance insomnia," showing only minimal benefit (10 min reduction in sleep latency, 8 min reduction in wake after sleep onset) with no improvement in subjective sleep quality compared to placebo. 7
Additional Mirtazapine Considerations
- Mirtazapine causes significant somnolence (54% vs 18% placebo) and weight gain (7.5% gained ≥7% body weight vs 0% placebo), which may be beneficial or problematic depending on patient context 4
- Exercise particular caution in elderly patients, as clearance is reduced by 40% in elderly males 4
Comparative Safety Data
A recent large retrospective study comparing low-dose quetiapine, trazodone, and mirtazapine for insomnia in older adults found no significant mortality difference between trazodone and mirtazapine groups, supporting mirtazapine's relative safety profile. 8
The evidence unequivocally supports mirtazapine over trazodone for sleep in patients with QTc prolongation, given trazodone's documented arrhythmogenic potential and FDA contraindication in this population. 1, 2